Navigation Links
Novel discovery by Einstein scientists could lead to much-needed kidney failure treatment
Date:3/12/2008

March 12, 2008 (BRONX, NY) The unwanted activation of an important cell-signaling pathway may play a role in two kidney problems that are major causes of end-stage renal disease, scientists at the Albert Einstein College of Medicine of Yeshiva University have found. Their research, which opens up a novel approach for treating kidney failure, is described in the March issue of Nature Medicine. The study was led by Dr. Katalin Susztak, an assistant professor of medicine (nephrology) at Einstein.

The kidneys filter waste products from the blood and maintain the bodys fluid balance by producing urine. The filtration is carried out by numerous capillary tufts within the kidney known as glomeruli. Kidney disease occurs when glomeruli become damaged and can no longer perform their filtering function. Kidney damage may ultimately progress to end-stage renal disease, in which patients need dialysis or a kidney transplant.

The Einstein scientists focused on cells known as podocytes that line the glomeruli. Since dysfunction of podocytes cells is important in progressive kidney disease, and since a cell-signaling pathway called Notch is crucial in podocyte development, the Einstein researchers reasoned that aberrant Notch signaling might play a role in causing kidney disease.

The Notch signaling pathway plays a key role in embryonic development of humans and most other multicellular organisms. The Notch pathway tells some cells to proliferate and others to undergo programmed cell death as it profoundly affects the way tissues are organized. Faulty Notch signaling has been found in several types of cancer and in many other diseases such as multiple sclerosis.

Collectively, the observations made in the Einstein study offer strong evidence that aberrant Notch signaling is also involved in diabetic nephropathy (DNP) and focal segmental glomerulosclerosis (FSGS)two of the major causes of end-stage renal disease. For example:

  • When comparing biopsy samples from healthy kidneys and kidneys from people with DNP and FSGS, the researchers found evidence that the Notch pathway was active in diseased but not in healthy kidneys.

  • The researchers bred a strain of mice in which they could specifically activate the Notch pathway within podocytes. Examination revealed that the podocytes in these mice underwent programmed cell death, and the mice themselves died from end-stage renal failure.

  • After inducing glomerular disease in mice by injecting them with a toxic chemical, the researchers were able to protect the rats from developing kidney disease by injecting them with a gamma secretase inhibitorone of a class of compounds known to shut off the Notch pathway.

An exciting aspect of this new work is the therapeutic implications, according to a Nature Medicine commentary on the Einstein study written by kidney experts from the University of Michigan Medical Center. The experts noted that gamma secretase inhibitors, like the one that protected the mice from kidney disease in this study, are already in phase 1 and 2 clinical trials for treating diseases including Alzheimers and leukemia. The Einstein findings, they wrote, provide some hope that researchers in the field of kidney disease can reverse the grim record of the last 20 years during which no new therapeutic agent has been successfully implemented for treating end-stage kidney disease.


'/>"/>

Contact: Karen Gardner
kgardner@aecom.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related medicine news :

1. Scripps Florida awarded $7.6 million grant to develop novel treatment for Parkinsons disease
2. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
3. USC researchers discover novel way to develop tumor vaccines
4. Novel mechanism found that may boost impaired function of leukemia protein
5. Novel method to reveal drug targets
6. Novel link between excessive nutrient levels and insulin resistance
7. Novel organic metal hybrids that will revolutionize materials science and chemical engineering
8. Novel mathematical model predicts new wave of drug-resistant HIV infections in San Francisco
9. Novel approach strips staph of virulence
10. UCSD research team identifies novel anticancer drug from the sea
11. Novel compound may lessen heart attack damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... San Jose, CA (PRWEB) , ... April 25, ... ... in cross-screen access, support, and collaboration, announces Mirroring360 Pro . This new ... providing a comprehensive collaboration experience for education and business. , Mirroring360 Pro enables ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... CFOs and HR decision-makers are preparing for how his administration could impact the ... provide insight into what changes are most likely to make it through Congress. ...
(Date:4/25/2017)... Vegas, NV (PRWEB) , ... April 25, 2017 ... ... can now choose a modern procedure that achieves results in a fraction of ... in Las Vegas, NV, with Significance Dental Specialists, now offers this revolutionary ...
(Date:4/25/2017)... ... April 25, 2017 , ... Buyers and sellers in the thriving multi-billion ... head shops –can’t help but be heartened by the industry’s current surge. But another ... described as “skunk smell.” At last they can simply, safely and effectively end ...
(Date:4/25/2017)... ... 25, 2017 , ... There is no better place in South Florida to ... in the May issue of Consumer Reports focused on heart health. , The ... during and after coronary bypass and aortic valve replacement procedures. , Consumer Reports ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
(Date:4/20/2017)... 2017 Research and Markets has announced ... Services Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, ... 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing services ... Low drug registration cost in Latin American countries ...
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
Breaking Medicine Technology: